» LEARN MORE ABOUT COVID-19 VACCINES, TESTING, VISITOR & SAFETY REQUIREMENTS

MyHealth

Manage your account, request prescriptions, set up appointments & more.

LOG IN
Don't have an account
Contact Us
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label

COG-ARST0531

Trial

Clinical Trial Title

Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma

Trial Status

Closed to Enrollment

Start Date

May 14, 2008

Trial Type

Pediatric Cancer (Oncology)

Specific Condition

Rhabdomyosarcoma (Intermediate Risk)

Description

This randomized phase III trial is studying two different combination chemotherapy regimens to compare how well they work when given together with radiation therapy in treating patients with newly diagnosed rhabdomyosarcoma. Drugs used in chemotherapy, such as vincristine sulfate, dactinomycin, cyclophosphamide, and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together with radiation therapy may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective when given together with radiation therapy in treating patients with rhabdomyosarcoma.

Eligibility Criteria

All patients must enroll on D9902 prior to enrollment on ARST0531 (refer to D9902 for requirements of tissue submission and time limitations for submission)

The results of rapid central review as part of D9902 must be received prior to Week 4 of protocol therapy

Patients must start protocol therapy within 42 days of the date of the pathology report that establishes the diagnosis of rhabdomyosarcoma (RMS)

Age: < 50 years at the time of enrollment

Newly diagnosed embryonal RMS, botryoid or spindle cell variants of embryonal RMS, ectomesenchymoma, or alveolar RMS are eligible for this study

Enrollment on D9902 to confirm local histologic diagnosis with central pathology review is required

Patients may be enrolled on ARST0531 and start protocol treatment prior to receipt of central pathology review results

Intermediate risk RMS is defined as: a) embryonal, botryoid, or spindle cell RMS, or ectomesenchymoma: Stage 2 or 3 and Group III OR b) alveolar RMS Stage 1-3 and Group I-III

Patients who have received prior chemotherapy (excluding steroids) or radiation therapy, except for patients transferring from ARST0331 (low-risk study), are not eligible

Adequate kidney, liver, and bone marrow function

No evidence of uncontrolled infection

Notes

https://clinicaltrials.gov/ct2/show/NCT00354835

Study status is:
Completed: The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Principal Investigator Name

Janice Olson, MD

Contact Name

Children's Cancer and Blood Disorders Program

Phone

(503) 276-9300

Last Updated: Wednesday, January 27, 2021 11:41:31 AM